Rapamycin, NAD and the Truth About Slowing Aging: Dr. Matt Kaeberlein
The most promising drug for slowing aging may already exist, and we still do not know whether healthy people should take it. Matt Kaeberlein has spent his career on mTOR, rapamycin and the mechanisms that might extend healthy lifespan, which makes him one of the few people qualified to say how far the field has actually come. What follows is unusually careful for a longevity conversation. He makes the case for rapamycin, then spends just as long on what the evidence does not yet show.
Chapters jump into the video
What aging actually is
Kaeberlein starts where most longevity conversations skip ahead: defining the thing. Aging is not one process with one cause, and the tidy lists that circulate online tend to flatten that. Getting the definition right is not academic housekeeping. It decides what counts as an intervention, what counts as evidence that one worked, and which outcomes are worth measuring in the first place.
Are the Hallmarks of Aging causes or consequences?
The Hallmarks framework organises the field, but Kaeberlein questions how much of it describes drivers rather than downstream effects. The practical test he keeps returning to: if you fix one hallmark completely, what actually happens to disease and function? His answer is that changing a single pathway or a single biomarker very often fails to produce the health outcome people expect, which is a problem for any programme built on hitting one target at a time. Aubrey de Grey made the opposite case in episode 14, and the two disagreements are worth reading against each other.
mTOR, and whether it is bad for you
mTOR is the pathway that made rapamycin interesting, and it is also where the popular version of the story goes wrong. mTOR is not a villain to be switched off. It is a nutrient-sensing system that cells need, which is why the interesting question is about modulation, timing and dose rather than suppression. Kaeberlein is careful to separate what the biology supports from the simplified version that circulates as advice.
Rapamycin, muscle growth and sarcopenia
The most common objection to rapamycin in a longevity context is that inhibiting mTOR should blunt muscle protein synthesis and accelerate age-related muscle loss. Kaeberlein's answer is that this does not follow as directly as the mechanism suggests. Intermittent dosing behaves differently from the continuous immunosuppressive regimens the fear is borrowed from, and the animal data does not show the muscle catastrophe the argument predicts.
How strong the rapamycin evidence actually is
This is the core of the episode. Rapamycin has some of the strongest preclinical evidence of any candidate longevity intervention, having extended lifespan across multiple animal models rather than in one lucky strain. Decades of use in transplant medicine tell us a great deal about its safety profile, with the important caveat that longevity dosing is very different from transplant dosing. What is missing is the part that matters most: whether any of it translates meaningfully to healthy humans. Kaeberlein says so plainly rather than filling the gap with confidence.
Why he takes it himself, and what ME/CFS has to do with it
Kaeberlein uses rapamycin periodically, and he is open that this is a personal decision made under uncertainty rather than a recommendation that follows from the data. He walks through the side effects honestly, and through emerging evidence in chronic inflammation, ME/CFS and long COVID, including what the chronic fatigue signal does and does not establish. Autophagy comes up here as the mechanism people reach for, and he keeps the explanation closer to the evidence than the usual version.
NAD supplements and the stacking problem
On NAD precursors his position is blunt: the human evidence remains weak, whatever the marketing says. He extends that into a broader warning about stacking large numbers of supplements with uncertain individual effects and entirely unknown combined ones. Taking twenty things at once does not multiply your odds of benefit. It multiplies the ways the experiment can go wrong while destroying your ability to tell what did anything.
Biological age clocks, and the markers he does trust
Consumer biological age tests are, in his assessment, far less useful than their marketing suggests. That is not a claim that the underlying science is worthless, but that the gap between a research instrument and a product sold to individuals is much wider than buyers are told. He does name the aging biomarkers he considers trustworthy, which is the more useful half of the answer. Dr. Anand Vinjamoori made a similar argument in episode 8 about treating biomarkers as signal rather than scripture.
Dogs, escape velocity and what he would change
The Dog Aging Project is his answer to the translation problem. Companion dogs share our environment, develop the same age-related diseases, and live long enough to make a trial meaningful without requiring a human lifetime to read out. Asked about longevity escape velocity he is unconvinced by the framing, and on the comparison people actually want, rapamycin against GLP-1 receptor agonists against metformin, he weighs where the evidence genuinely sits rather than picking a side.
Key takeaways
Kaeberlein questions how much of the Hallmarks framework describes causes rather than consequences, and points out that fixing one pathway or biomarker often fails to produce the expected health outcome. mTOR is a system to modulate, not a villain to suppress, and the argument that rapamycin must accelerate muscle loss does not follow as directly as the mechanism suggests. Rapamycin has the strongest preclinical evidence of any candidate longevity drug and decades of safety data from transplant medicine at very different doses, but whether it helps healthy humans is still unanswered. He uses it periodically as a personal decision under uncertainty. Human evidence for NAD supplements remains weak, stacking many supplements multiplies the unknowns, and most consumer biological age tests are oversold. Dogs may be the most useful bridge between animal data and human aging.
Questions this episode answers
Can rapamycin really slow aging?
In animals the case is strong: rapamycin has extended lifespan across multiple models, which gives it some of the best preclinical evidence of any candidate longevity intervention. Whether that translates to healthy humans is the open question, and Kaeberlein treats it as genuinely unanswered rather than as a formality.
How strong is the human evidence for rapamycin?
Weaker than the enthusiasm around it suggests. Decades of transplant medicine tell us a lot about safety, but at doses very different from those used for longevity, and there is no trial showing healthy people live longer or better on it.
What are the main risks and side effects of rapamycin?
Kaeberlein walks through them directly in the episode rather than glossing over them. The key distinction he draws is between the continuous immunosuppressive dosing used in transplant medicine and the intermittent dosing used in a longevity context, which behave differently.
Does rapamycin interfere with muscle growth?
The mechanistic worry is that inhibiting mTOR should blunt muscle protein synthesis and accelerate sarcopenia. Kaeberlein argues this does not follow as directly as the mechanism implies, since intermittent dosing is not the same as continuous suppression and the animal data does not show the muscle loss the argument predicts.
Why does Matt Kaeberlein take rapamycin himself?
He uses it periodically, and he is explicit that this is a personal decision made under uncertainty rather than a recommendation that follows from the evidence. He separates the two more carefully than most people in the field.
Could rapamycin help with chronic inflammation or ME/CFS?
There is emerging evidence he takes seriously, including signals in chronic fatigue and long COVID. He is careful about what those findings establish, which is considerably less than the headlines around them suggest.
Is there strong evidence for NAD supplements?
No. Kaeberlein's position is that human evidence for NAD precursors remains weak despite how confidently they are marketed.
Is it a problem to take many supplements at once?
He warns against it. Stacking twenty compounds with uncertain individual effects and unknown combined effects does not multiply the chance of benefit, it multiplies the ways things can go wrong while making it impossible to tell what did anything.
Are biological age tests useful yet?
Most consumer-facing ones are far less useful than their marketing suggests. The gap between a research instrument and a product sold to individuals is much wider than buyers are told, though he does name the aging biomarkers he considers trustworthy.
Are the Hallmarks of Aging causes or consequences?
Kaeberlein questions how much of the framework describes actual drivers rather than downstream effects. His practical test is what happens to disease and function when you fix one hallmark completely, and his observation is that changing a single pathway or biomarker often fails to produce the expected health outcome.
Is longevity escape velocity scientifically plausible?
He is unconvinced by the framing. It comes up alongside the question of whether AI could accelerate aging research, and he applies the same standard to both: interesting, but not a substitute for evidence that an intervention works.
Rapamycin, GLP-1 drugs or metformin: where is the strongest evidence?
He weighs the three directly rather than picking a favourite. The comparison is useful precisely because the three sit at very different points on the evidence curve, and because the strongest preclinical case and the strongest human case are not held by the same drug.
Why study aging in dogs?
Companion dogs share our environment, develop the same age-related diseases and live long enough for a trial to be meaningful without taking a human lifetime to read out. That is the logic behind the Dog Aging Project, which Kaeberlein co-founded.